Astel­las/Fi­bro­Gen's ane­mia drug for CKD pa­tients ap­proved in Japan; Re­searchers pro­pose com­bo to stay ahead of KRAS re­sis­tance

→ Rox­adust, a treat­ment for ane­mia that aris­es as a com­pli­ca­tion in chron­ic kid­ney dis­ease, has been ap­proved in Japan. De­vel­oped by Fi­bro­Gen and Astel­las Phar­ma, the drug works dif­fer­ent­ly than the ery­thro­poiesis-stim­u­lat­ing agents cur­rent­ly used to treat ane­mia in CKD. A HIF-PH in­hibitor, it ac­ti­vates a nat­ur­al body re­sponse to re­duced oxy­gen in the blood, the com­pa­ny said.

Ane­mia in CKD can wors­en com­pli­ca­tions, in­creas­ing the like­li­hood of car­dio­vas­cu­lar in­ci­dents and quick­en­ing pro­gres­sion to re­nal fail­ure. The drug has al­so been ap­proved in Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER